Financials

  • Market Capitalization 8.06 B
  • Employee 691
  • Founded 2014
  • CEO Rich Adcock
  • Website www.immunitybio.com
  • Headquarter Delaware, United States
  • FIGI BBG007T9DYW9
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-9.02
Relación precio/flujo de caja
51.72

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
1023
TGTX
TG Therapeutics, Inc. - Common Stock
55.37 USD+0.87%-2.19%+10.43%+44.61%8.48 B USD
1033
PCVX
Vaxcyte, Inc. - Common Stock
56.45 USD+0.43%-1.31%+13.88%+33.45%8.15 B USD
1042
IMVT
Immunovant, Inc. - Common Stock
39.23 USD+1.19%+0.72%+18.13%+104.22%8.05 B USD
1061
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
62.03 USD+0.08%-2.04%+18.83%+56.46%7.76 B USD

Noticias